ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Tevogen Bio Holdings Inc

Tevogen Bio Holdings Inc (TVGN)

1.36
0.03
(2.26%)
終了 11月20日 6:00AM
1.72
0.36
( 26.47% )
プレマーケット: 9:13PM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
1.72
買値
1.72
売値
1.73
出来高
6,305,952
0.00 日の範囲 0.00
0.2556 52 週間の範囲 21.09
時価総額
前日終値
1.36
始値
-
最終取引時間
21:13:34
財務取引量
-
VWAP
-
平均取引量 (3 か月)
16,817,770
発行済株式数
170,646,864
配当利回り
-
PER
-3,400.00
1 株当たり利益 (EPS)
-0
歳入
-
純利益
-67k

Tevogen Bio Holdings Inc について

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

セクター
Biological Pds,ex Diagnstics
業界
Blank Checks
ウェブサイト
本社
Wilmington, Delaware, USA
設立
2024
Tevogen Bio Holdings Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker TVGN. The last closing price for Tevogen Bio was US$1.36. Over the last year, Tevogen Bio shares have traded in a share price range of US$ 0.2556 to US$ 21.09.

Tevogen Bio currently has 170,646,864 shares in issue. The market capitalisation of Tevogen Bio is US$232.08 million. Tevogen Bio has a price to earnings ratio (PE ratio) of -3400.00.

TVGN 最新ニュース

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023...

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen’s success...

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen’s success...

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending.Approximately 78% of Tevogen Bio's common stock is held by...

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.Tevogen Bio created a data set containing known proteins in the HPV genome to identify...

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen’s approach has the potential to shorten timelines and substantially reduce costs. Tevogen’s AI...

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Regained compliance without effecting a reverse stock splitTevogen Bio CEO reaffirms his commitment to preserve shareholder value WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio...

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

CD8 Technology Services, LLC (“CD8 Technology”) to provide turn-key facility for Tevogen BioReinforces Tevogen Bio’s commitment to preserving shareholder valueExpected to further enhance Tevogen...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.11-6.010928961751.832.031.2620235311.53572055CS
4-0.17-8.994708994711.893.091.01138683152.36402055CS
121.1473200.331761830.57273.090.2556168177701.56833066CS
260.87102.3529411760.853.090.255679112771.55140881CS
52-2.38-58.04878048784.121.090.255655637001.57044536CS
156-2.38-58.04878048784.121.090.255655637001.57044536CS
260-2.38-58.04878048784.121.090.255655637001.57044536CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
SLXNSilexion Therapeutics Corporation
US$ 0.4149
(83.42%)
26.31M
QSIQuantum Si Inc
US$ 1.01
(59.56%)
3.45M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.2427
(49.17%)
66.66M
FFNWFirst Financial Northwest Inc
US$ 30.99
(39.28%)
92
KITTNauticus Robotics Inc
US$ 1.25
(37.33%)
21.46M
AHCOAdaptHealth Corporation
US$ 6.11
(-37.27%)
1
WSBFWaterstone Financial Inc
US$ 10.12
(-33.64%)
3
FSTRL B Foster Company
US$ 18.00
(-29.99%)
5
PFCPremier Financial Corporation
US$ 20.00
(-27.64%)
202
XNCRXencor Inc
US$ 17.11
(-27.59%)
2
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.2427
(49.17%)
66.66M
DBGIDigital Brands Group Inc
US$ 0.1347
(15.52%)
32.19M
SLXNSilexion Therapeutics Corporation
US$ 0.4149
(83.42%)
26.31M
KITTNauticus Robotics Inc
US$ 1.25
(37.33%)
21.46M
XXII22nd Century Group Inc
US$ 0.0981
(0.62%)
11.68M

TVGN Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock